What's Behind Bristol-Myers Squibb's High Valuation?

By Max Macaluso and Dave Williamson – Aug 21, 2013 at 11:00AM

NYSE: BMY

Bristol Myers Squibb

Market Cap

$99B

Today's Change

(-0.27%) -$0.13

Current Price

$48.86

Price as of April 24, 2024, 4:00 p.m. ET

Shares of Bristol-Myers Squibb have soared this year --- but what's been driving this growth?

Shares of Bristol-Myers Squibb (BMY -0.27%) have soared more than 27% since the start of this year, surpassing not only the S&P 500, but also its peers Eli Lilly (LLY -1.81%) and AstraZeneca (AZN 0.49%). What have been the main drivers of this growth, and how is Bristol-Myers valued today compared to other stocks in this competitive industry? In the following segment, taken from The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss an important valuation metric that all investors should pay attention to and why Bristol-Myers trades at a premium to many of its peers.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.